

Original Article



Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014–2016

Yung-Taek Ouh ,^{1,*} Kyung-Jin Min ,^{2,*} Hyun Woong Cho ,¹ Moran Ki ,³
Jin-Kyoung Oh ,³ Sang Yop Shin ,⁴ Jin Hwa Hong ,¹ Jae-Kwan Lee ¹

¹Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

²Department of Obstetrics and Gynecology, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea

³Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

⁴Department of Internal Medicine, Korea Medical Institute, Seoul, Korea

OPEN ACCESS

Received: Jul 18, 2017

Revised: Oct 20, 2017

Accepted: Oct 25, 2017

Correspondence to

Jae-Kwan Lee

Department of Obstetrics and Gynecology,
Korea University Guro Hospital, Korea
University College of Medicine, 148
Gurodong-ro, Guro-gu, Seoul 08308, Korea.
E-mail: jklee38@korea.ac.kr

*Yung-Taek Ouh and Kyung-Jin Min
contributed equally to this work.

Copyright © 2018. Asian Society of
Gynecologic Oncology, Korean Society of
Gynecologic Oncology

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License ([https://
creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/))
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

Yung-Taek Ouh

<https://orcid.org/0000-0001-5887-4497>

Kyung-Jin Min

<https://orcid.org/0000-0002-5783-4968>

Hyun Woong Cho

<https://orcid.org/0000-0002-7114-6301>

Moran Ki

<https://orcid.org/0000-0002-8892-7104>

<https://ejgo.org>

ABSTRACT


Objective: Knowledge regarding the prevalence and distribution of human papillomavirus (HPV) genotyping in healthy women is important in establishing strategies for cervical cancer screening and HPV vaccination.

Methods: A total of 18,170 women who visited a Korean Medical Institute for health check-ups were recruited retrospectively; they underwent HPV genotyping and conventional cervical cytology. An HPV DNA test was performed using the Anyplex™ II HPV 28 detection system (Seegene) or HPV Liquid Bead Microarray (Osang Healthcare). The distribution of HPV genotypes was assessed according to cervical cytology and age.


Results: HPV was detected in 3,037 (16.71%) of the 18,170 women enrolled, and 2,268 (12.48%) were positive for high-risk (HR) HPV. In total, HPV 53 (9.69% of all detected HPV viruses) was the most common type; HPV 58 (7.90%) and 52 (7.81%) were also common. HPV 54 (6.99%) was common in low-risk subjects. Overall and in the normal cytology group, the most common HPV genotype was HPV 53, whereas HPV 58 was more common in women who had atypical squamous cells of undetermined significance or low-grade squamous intraepithelial neoplasia cervical cytology. In addition, HPV 16 was the most common type in cases with high-grade squamous intraepithelial neoplasia (HSIL)/atypical squamous cells—cannot exclude HSIL. Among women with normal cytology, 76 of 231 (32.9%) women under 24 years of age were positive for HR HPV, whereas 84 of 852 (9.9%) women aged 55–59 years were positive.

Conclusion: HPV 53 was the most prevalent genotype in healthy women. Distribution of HPV genotypes varied with cervical cytology and age. Our study provides important baseline data for the recently implemented national HPV vaccination program.

Keywords: Human Papilloma Virus; Cervical Intraepithelial Neoplasia; Papanicolaou Test

Jin-Kyoung Oh 
<https://orcid.org/0000-0001-9331-3054>

 Sang Yop Shin 
<https://orcid.org/0000-0003-2174-4247>

 Jin Hwa Hong 
<https://orcid.org/0000-0002-6905-5363>

 Jae-Kwan Lee 
<https://orcid.org/0000-0002-9727-3587>

Funding

This research was supported by a fund (2016E3200600) by Research of Korea Centers for Disease Control and Prevention.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: M.K.J., O.J.K., H.J.H., L.J.K.; Formal analysis: K.M.; Investigation: C.H.W., S.S.Y., O.J.K.; Methodology: K.M.; Resources: S.S.Y.; Supervision: H.J.H., L.J.K.; Validation: C.H.W., O.J.K., L.J.K.; Visualization: L.J.K.; Writing - original draft: O.Y.T., M.K.J.; Writing - review & editing: O.Y.T., M.K.J.

INTRODUCTION

The prevalence of cervical cancer remains high in Korea, despite a decreasing trend [1]. Korean screening guidelines for the prevention of cervical cancer call for a conventional Pap smear or liquid-based cytology every 3 years for asymptomatic women; an additional optional human papillomavirus (HPV) test is also recommended [2]. Because primary HPV screening can lower cancer risk compared to conventional cytology-only screening, it has been considered a viable alternative [3]. HPV is the most important factor that induces transformation of cervical epithelial cells into precancerous lesions or cancer [4]. HPV infection status is thus a crucial element in cervical cancer screening. Consequently, the HPV test has emerged as an important screening tool [5,6].

Many countries have carried out large-scale vaccination projects that have been highly efficient and lifesaving against cervical cancer [5,7]. Gardasil® is a commonly used quadrivalent vaccine against HPV types 6, 11, 16, and 18; HPV types 6 and 11 are low-risk (LR) genotypes that induce genital warts or condylomas [8]. Gardasil 9, approved by the United States Food and Drug Administration (US FDA) in 2014, provides protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 [9]. The preventive efficacy of the HPV vaccine against infection has been proven in several studies [8,10,11]. However, all high-risk (HR) HPV types that could cause cervical cancer are not fully covered by Gardasil 9, and prevalent HPV types vary among countries [12]. In addition, various HPV types have different HPV-attributable cancer burdens [13].

Although many studies have reported the prevalence of HPV genotypes based on the presence of precancerous lesions and invasive cancer [14-16], a reliable, large-population study has not been reported previously. For these reasons, it is very important to investigate HPV prevalence and type distribution according to cytology and age in Korea. We reviewed data from women who visited a large private Korean healthcare company, and, based on these cross-sectional data, evaluated the prevalence of HPV genotypes according to cervical cytology and age.

MATERIALS AND METHODS

1. Study population

A total of 18,170 women aged 17 to 83 years who visited a large private healthcare company consisting of 7 centers nationwide from January 2014 to December 2016 were included in this study. All patients underwent a gynecologic examination that included collection of a cervical sample for HPV DNA genotyping and cervical cytology via a Papanicolaou-stained conventional smear. Abnormal cytology was reported by pathologists according to the 2001 Bethesda system [17]. The samples were classified as: atypical squamous cells of undetermined significance (ASCUS); atypical squamous cells-cannot exclude high-grade squamous intraepithelial neoplasia (ASC-H); low-grade squamous intraepithelial neoplasia (LSIL); high-grade squamous intraepithelial neoplasia (HSIL); atypical glandular cells (AGC); or unsatisfactory.

All specimens and related data were obtained with approval from the Institutional Review Board of Korea University Guro Hospital (KUGH16216-001).

2. HPV DNA testing

HPV genotyping was done via 2 different methods. Between January 2014 and March 2016, 10,839 samples were analyzed with the HPV Liquid Bead Microarray (Osang Healthcare, Anyang, Korea), which detected 32 types of HPV (6, 11, 16, 18, 26, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 62, 66, 68, 69, 70, 73, 81, and 83). Between April and December 2016, 7,331 samples were analyzed with Anyplex™ II HPV 28 (Seegene, Seoul, Korea), which detected 28 types of HPV (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, and 82). We classified HPV into 19 HR HPV strains (HR HPVs; 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, and 82) and 9 LR HPV strains (LR HPVs; 6, 11, 40, 42, 43, 44, 54, 61, and 70) [18].

1) HPV Liquid Bead Microarray

The microarray utilized type-specific oligonucleotide probes for 32 genotypes of HPV DNA, and was based on DNA sequences of the viral L1 gene and specific probes coupled to carboxylated beads (Luminex, Austin, TX, USA). Oligonucleotides, carried by each bead, were ultimately mixed and are referred to as the bead mix. Single-strand polymerase chain reaction (PCR) was used to label the complementary sequences of the probe (Invitrogen, Carlsbad, CA, USA). Thirty-five cycles of amplification were followed by a 5-minute denaturation step at 94°C: denaturation for 30 seconds at 94°C, annealing at 58°C for 1 minute and elongation at 72°C for 2 minutes. The hybridization buffer and HPV mix containing beads were affixed to the PCR products. Then, hybridization was carried out and consequently transferred to a filter plate. Beads were analyzed for R-phycoerythrin receptor fluorescence in the Luminex 100 IS system (Luminex).

2) Anyplex™ II HPV 28

We carried out extraction of HPV DNA in accordance with the manufacturer's guidelines. This real-time PCR test detects 28 HPV DNA genotypes using dual priming oligonucleotides (DPO™, Seegene) and a melting curve analysis method of tagging oligonucleotide cleavage and extension (TOCE™, Seegene). TOCE predicted the melting temperature of the Catcher duplex and offered real-time PCR to HPV 28 using a predetermined target sequence. The L1 gene and human β -globin were amplified concurrently and we measured fluorescence continuously with increasing temperature.

3. Statistical analysis

Age data are presented as the mean \pm standard deviation. The distribution of HPV genotypes was analyzed by Bethesda system-based cervical cytology and age was divided into 5-year groups. For comparing groups, we used the χ^2 test or Fisher's exact test. $p < 0.05$ was considered statistically significant. The data were analyzed with SPSS version 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS

1. Baseline characteristics

A total 18,170 patients were enrolled with valid results for Anyplex™ II HPV 28 or HPV Liquid Bead microarray cytology. The distributions of age and cervical cytology in patients are presented in **Table 1**. The mean age was 41.40 years. In terms of cervical cytology, 17,717 women (97.51%) had normal cytology, 228 women (1.25%) had ASCUS, 151 women (0.83%) had LSIL, and 50 women (0.27%) had HSIL/ASC-H. Among the 3,037 (16.7%) women who

Table 1. Distribution of age, cervical cytology, and HPV prevalence in enrolled patients (n=18,170)

Characteristics	Mean/frequency
Age (yr)	41.40
<25	253 (1.39)
25–29	1,397 (7.69)
30–34	2,615 (14.39)
35–39	3,897 (21.45)
40–44	4,179 (23.00)
45–49	2,757 (15.17)
50–54	1,309 (7.20)
55–59	870 (4.79)
60–64	512 (2.82)
65–69	248 (1.36)
70–74	87 (0.48)
≥75	46 (0.25)
Cervical cytology	
Normal	17,717 (97.51)
ASCUS	228 (1.25)
LSIL	151 (0.83)
ASC-H	11 (0.06)
HSIL	39 (0.21)
AGC	6 (0.03)
Unsatisfactory	18 (0.11)
HPV	
Any genotype* (HR and/or LR)	3,037 (16.7)
Single	2,154 (11.8)
Multiple	883 (4.9)
19 HR*	2,268 (12.5)
Single	1,712 (99.4)
Multiple	556 (3.1)

Values are presented as mean or number (%).

AGC, atypical glandular cells; ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial neoplasia; ASCUS, atypical squamous cells of undetermined significance; HPV, human papillomavirus; HR, high-risk; HSIL, high-grade squamous intraepithelial neoplasia; LR, low-risk; LSIL, low-grade squamous intraepithelial neoplasia.

*HR HPV includes HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, and 82. LR HPV includes HPV types 6, 11, 40, 42, 43, 44, 54, 61, and 70.

were positive for HR and/or LR HPV, 2,268 women (12.5%) had HR HPV. Single infections were more common than multiple infections in both the any-HPV genotype group and the HR HPV group.

2. HPV prevalence

With regard to HPV prevalence, 2,874 HR HPVs and 1,430 LR HPVs were detected in the overall population (**Table 2**). Among the detected types of HPV, HR HPV 53 was the most frequent type (9.69%), followed by HR HPV 58 (7.90%), HR HPV 52 (7.81%), LR HPV 54 (6.99%), LR HPV 70 (6.41%), HR HPV 16 (5.86%), HR HPV 39 (5.62%), HR HPV 68 (4.93%), HR HPV 51 (4.14%), and HR HPV 56 (4.04%; **Fig. 1**).

3. HR HPV positivity by cervical cytology grade

The overall prevalence of the 19 HR HPVs was higher in ASCUS/LSIL cytology than in normal cytology. The prevalence of the 19 HR HPVs increased with increasing cervical cytology severity ($p=0.028$); HR HPVs were detected in 2,012 (11.4%) of 17,717 cases with normal cytology, 92 (40.4%) of 228 ASCUS cases, 113 (74.8%) of 151 LSIL cases and 45 (90.0%) of 50 HSIL/ASC-H cases (**Table 3**). However, the risk of multiple infection did not show the same pattern ($p=0.211$).

Table 2. Distribution of different detected HPV genotypes

HPV genotype	No. of patients	HR HPV or LR HPV infection (%)	HPV/any HPV infection (%)
19 HR HPV strains			
16	252	8.77	5.86
18	125	4.35	2.90
26	8	0.28	0.19
31	86	2.99	2.00
33	56	1.95	1.30
35	116	4.04	2.70
39	242	8.42	5.62
45	70	2.44	1.63
51	178	6.19	4.14
52	336	11.69	7.81
53	417	14.51	9.69
56	174	6.05	4.04
58	340	11.83	7.90
59	63	2.19	1.46
66	140	4.87	3.25
68	212	7.38	4.93
69	25	0.87	0.58
73	16	0.56	0.37
82	18	0.63	0.42
Total	2,874	100	66.78
9 LR HPV strains			
6	102	7.13	2.37
11	38	2.66	0.88
40	142	9.93	3.30
42	164	11.47	3.81
43	149	10.42	3.46
44	162	11.33	3.76
54	301	21.05	6.99
61	96	6.71	2.23
70	276	19.30	6.41
Total	1,430	100	33.22
Total	4,304	100	100

Values are presented as frequencies or percentages.
HPV, human papillomavirus; HR, high-risk; LR, low-risk.




Fig. 1. Distribution of HR and LR HPV types among Korean women. HR HPV includes HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, and 82. LR HPV includes HPV types 6, 11, 40, 42, 43, 44, 54, 61, and 70.
HPV, human papillomavirus; HR, high-risk; LR, low-risk.

HPV prevalence in the Republic of Korea

Table 3. Positivity for HR HPV by cervical cytology grade

HPV	Normal (n=17,717)	ASCUS (n=228)	LSIL (n=151)	HSIL/ASC-H (n=50)	p-value
19 HR HPV* (+)	2,012 (11.4)	92 (40.4)	113 (74.8)	45 (90.0)	0.028
Single	1,537 (8.7)	70 (30.7)	73 (48.3)	27 (60.0)	
Multiple	475 (2.7)	22 (9.7)	40 (26.5)	18 (30.0)	
19 HR HPV (-)	15,705 (88.6)	136 (59.6)	38 (25.2)	5 (10.0)	

Values are presented as number of cases (%).

ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial neoplasia; ASCUS, atypical squamous cells of undetermined significance; HPV, human papillomavirus; HR, high-risk; HSIL, high-grade squamous intraepithelial neoplasia; LR, low-risk; LSIL, low-grade squamous intraepithelial neoplasia.

*HR HPV includes HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, and 82.

Table 4. Prevalence of HR HPV genotypes by cervical cytology

HPV	Genotype	Normal	ASCUS	LSIL	HSIL/ASC-H	p-value
19 HR	16	214 (8.44)	13 (10.16)	9 (5.39)	16 (24.62)	<0.001
	18	109 (4.30)	4 (3.13)	10 (5.99)	2 (3.08)	<0.001
	26	8 (0.32)	0 (0)	0 (0)	0 (0)	1.000
	31	77 (3.04)	1 (0.78)	3 (1.80)	5 (7.69)	<0.001
	33	48 (1.89)	2 (1.56)	3 (1.80)	3 (4.62)	<0.001
	35	103 (4.06)	3 (2.34)	5 (2.99)	5 (7.69)	<0.001
	39	218 (8.59)	8 (6.25)	13 (7.78)	3 (4.62)	<0.001
	45	66 (2.60)	1 (0.78)	2 (1.20)	1 (1.54)	0.102
	51	152 (5.99)	9 (7.03)	14 (8.38)	3 (4.62)	<0.001
	52	295 (11.63)	20 (15.63)	10 (5.99)	9 (13.85)	<0.001
	53	377 (14.86)	15 (11.72)	22 (13.17)	2 (3.08)	<0.001
	56	147 (5.79)	6 (4.69)	20 (11.98)	0 (0.00)	<0.001
	58	282 (11.12)	21 (16.41)	29 (17.37)	8 (12.31)	<0.001
	59	54 (2.13)	4 (3.13)	2 (1.20)	3 (4.62)	0.001
	66	114 (4.49)	11 (8.59)	11 (6.59)	2 (3.08)	<0.001
	68	194 (7.65)	6 (4.69)	10 (5.99)	1 (1.54)	<0.001
	69	21 (0.83)	2 (1.56)	2 (1.20)	0 (0)	0.021
73	15 (0.59)	0 (0)	1 (0.60)	0 (0)	0.178	
82	43 (1.69)	2 (1.56)	1 (0.60)	2 (3.08)	0.005	
	Total	2,537 (100)	128 (100)	167 (100)	65 (100)	

Values are presents as number of patients (%).

ASCUS, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial neoplasia; HPV, human papillomavirus; HR, high-risk; HSIL, high-grade squamous intraepithelial neoplasia; LSIL, low-grade squamous intraepithelial neoplasia.

4. Prevalence of HR HPV genotypes by cervical cytology

The proportion of HR HPV genotypes detected according to cervical cytology is shown in **Table 4**. HR HPV 53 was the most frequently detected genotype in normal cytology cases (14.86%). HR HPV 52 (11.63%) and HPV 58 (11.12%) were also common types detected in normal cytology cases. In patients with ASCUS, HR HPV 58 was the most frequent genotype (12.50%), followed by HR HPV 52 (11.90%), HR HPV 53 (8.93%), and HR HPV 16 (7.74%). Similarly, HR HPV 58 was the most frequently detected type in LSIL (13.81%), and the next most frequent types were HR HPV 53 (10.48%), HR HPV 56 (9.52%), and HR HPV 51 (6.67%). The percentage of cases of with HPV 16 detected among the HR HPV genotypes was 24.62%, and was markedly higher in the HSIL/ASC-H group.

5. HPV prevalence in cases with normal cervical cytology and in ASCUS/LSIL cases by age group

HPV prevalence with normal cytology and in ASCUS/LSIL cases is shown stratified by age in **Table 5**. The rate of 19-HR HPV positivity was 11.4% in the normal cytology group and 54.1% in the ASCUS/LSIL group. Subdivided by age, normal cytology/19 HR HPV-positive results were most common in women younger than 24 years old (32.9%) and decreased with age, and

Table 5. 19 HR HPV positivity with normal cytology and ASCUS/LSIL by age group

Age	Normal	ASCUS/LSIL	HSIL/ASC-H	p-value
≤24	76/231 (32.9)	18/21 (85.7)		<0.001
25–29	330/1,334 (24.7)	37/52 (71.2)	7/7 (100.0)	<0.001
30–34	429/2,550 (16.8)	32/48 (66.7)	10/13 (76.9)	<0.001
35–39	339/3,819 (8.9)	42/65 (64.6)	8/9 (88.9)	<0.001
40–44	342/4,092 (8.4)	38/77 (49.4)	3/6 (50.0)	<0.001
45–49	234/2,678 (8.7)	15/67 (22.4)	5/9 (55.6)	<0.001
50–54	110/1,280 (8.6)	8/24 (33.3)	2/4 (50.0)	<0.001
55–59	84/852 (9.9)	12/16 (75.0)	1/2 (50.0)	<0.001
60–64	40/505 (7.9)	1/5 (20.0)		0.343
65–69	21/245 (8.6)	1/3 (33.3)		0.244
70–74	3/85 (3.5)	1/1 (100.0)		0.047
≥75	4/46 (8.7)			

Values are presented as number (%).

ASCUS, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial neoplasia; LSIL, low-grade squamous intraepithelial neoplasia.

the tendency reached a plateau at 8.9% in women aged 35–39 years. In total, 85.7% of ASCUS/LSIL patients younger than 24 were positive for an HR HPV, while 71.2%, 66.7%, 64.6%, 49.4%, and 22.4% of ASCUS/LSIL patients aged 25–29, 30–35, 35–39, 40–44, or 45–49 years, respectively, were positive for an HR HPV. The prevalence of the 19 HR HPVs increased with age, with 33.3% of women aged 50–54 and 75.0% aged 55–59 testing positive.

DISCUSSION

Among the 18,170 women who enrolled our study, 3,037 (16.7%) were positive for HPV and 2,268 (12.5%) were positive for HR HPV. A notable finding of this study was that HPV 53 was the most common type in Korea and HPV 58, 52, and 16 were also common. Among LR HPV types, HPV 54 and 70 were common. Obviously, HPV positivity was higher in women whose cervical cytology was most advanced (HSIL/ASC-H), higher in LSIL than ASCUS, and higher in ASCUS than in those with normal cytology. Overall and in the normal cytology groups, the most common HPV genotype was HPV 53, whereas HPV 58 was more common in women with ASCUS or LSIL cytology. In addition, HPV 16, widely known to be associated with invasive cervical cancer, was the most common type in HSIL/ASC-H cases [19]. When we classified cervical cytology into normal and ASCUS/LSIL, there was not a significant difference in the prevalence of the 19 HR HPVs among women <59 years old.

In a retrospective worldwide study of HPV-type distribution in invasive cervical cancer, 8,977 of 10,575 patients were positive for HPV. HPV 16 and 18 were the most common types, and those 2 types accounted for 71% of all HPV types detected in invasive cervical cancer [20]. HPV 58 was more frequently detected in Asian cervical cancer cases than in Europe or Africa. Forty-seven years of research on type-specific HPV prevalence among women with invasive cervical cancer in Korea found that HPV 16 (63.1%) was the most prevalent type in invasive cervical cancer, followed by HPV 18 (8.5%), HPV 33 (4.5%), and HPV 58 (3.9%) [21]. Although we did not investigate the prevalence of HPV types in invasive cervical cancer, HPV 16 (24.62%) was the most common type in patients with HSIL/ASC-H, which was the most severe classification in our study. Our findings were consistent with previous research, showing that HPV 16 is most common type in patients with precancerous neoplasia lesions both in Korea [22] and worldwide [14,23,24].

Another Korean study assessed data collected via health check-up from 2008 to 2010 at a single center. Of 7,014 women, 19.7% had HPV, which was higher than our results of 16.7%; however, their reported prevalence of HR HPV (8.4%) was lower than the current study (12.5%) [16]. In that study, the most frequently detected HPV genotypes among all women were HPV 58 (23.9%), HPV 16 (21.8%), HPV 52 (16.6%), and HPV 18 (11.7%), which is discordant with our results. The prevalence of HPV types in their report was 14.51% for HPV 53, 11.83% for HPV 58, 11.69% for HPV 52, and 8.77% for HPV 16, which was somewhat different from our results. However, since their study population had geographical limitations as a single institutional survey of individuals living in an urban setting, the distribution of HPV types in their results are unlikely to reflect national averages. According to recent reports in Korea, HPV prevalence is reported from as low as 16.7% to as high as 40.7% [16,25], depending upon the HPV detection method and target population. In particular, the study reporting HPV positivity of 40.7% had the highest prevalence because they targeted commercial sex workers [25]. Although our study population was from a single institution, there were broadly distributed branches nationwide, and so they more accurately represent Korean women in general.

We found that HPV 53 was the most prevalent type in Korea, which was inconsistent with previous Korean studies, [16,22,25-28] with one exception; So et al. [22] reported that the most common HPV type in Korea was HPV 53. Because we analyzed patients who visited 7 centers of Korea Medical Institute (KMI) nationwide in Korea, our results could more closely mirror the general population. In addition, our data were more recent, from January 2014 to December 2016, and the only large-population study in Korea to date, and so the results could be interpreted as indicating that the incidence of HPV 53 has increased over time. Unfortunately, although HPV 53 was the most frequent HPV type in our data, it is not an HPV genotype that Gardasil 9 targets. Nonetheless, HPV 53-related cervical cancer is very rare, not only in Korea, but also internationally [20,27,29].

This study has several limitations. First, we enrolled women who underwent health examinations at KMI, which was a private corporation. These results may not reflect the general population of Korea, since women who participated in our study were volunteers who were screened at KMI. Due to the small number of volunteers aged >50, the results may not be accurate for this age group. Furthermore, numerous women avoid HPV tests or Pap smears because of a fear of pelvic examinations [30]. Second, we could not access information on whether participants were vaccinated. However, it was important to analyze the present prevalence of HPV, so we focused on the standard HPV prevalence data for Korea. Lastly, HPV DNA testing was carried out using 2 different systems, the HPV Liquid Bead Microarray and Anyplex™ II HPV 28. Although both detection systems have been validated, [31,32] using 2 systems might be less accurate than using just one HPV genotyping method.

In conclusion, we described the prevalence and distribution of HPV genotypes by age and cytology for 18,170 women who voluntarily visited a healthcare institute. Knowledge of epidemiologic HPV genotypes will be helpful for creating effective HPV screening strategies and developing targeted, protective HPV vaccines. Furthermore, our study of HPV genotypes in Korea provides important baseline data for evaluating the effectiveness of the newly implemented National Immunization Program (NIP) HPV vaccine program. Further studies of changes in the prevalence and distribution of HPV genotypes after implementation of the NIP are needed.

REFERENCES

1. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. *Cancer Res Treat* 2017;49:292-305.
[PUBMED](#) | [CROSSREF](#)
2. Min KJ, Lee YJ, Suh M, Yoo CW, Lim MC, Choi J, et al. The Korean guideline for cervical cancer screening. *J Gynecol Oncol* 2015;26:232-9.
[PUBMED](#) | [CROSSREF](#)
3. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. *Gynecol Oncol* 2015;136:178-82.
[PUBMED](#) | [CROSSREF](#)
4. Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kühndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. *J Clin Virol* 2004;30:302-8.
[PUBMED](#) | [CROSSREF](#)
5. Campos NG, Mvundura M, Jeronimo J, Holme F, Vodicka E, Kim JJ. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. *BMJ Open* 2017;7:e015048.
[PUBMED](#) | [CROSSREF](#)
6. Tantitamit T, Termrungruanglert W, Khemapech N, Havanond P. A model approach for assessing the benefits of HPV testing against cytology in screening for cervical cancer precursors in Thailand. *Asian Pac J Cancer Prev* 2017;18:1271-5.
[PUBMED](#)
7. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. *J Manag Care Pharm* 2010;16:217-30.
[PUBMED](#) | [CROSSREF](#)
8. FUTURE I/II Study Group Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. *BMJ* 2010;341:c3493.
[PUBMED](#) | [CROSSREF](#)
9. Cuzick J. Gardasil 9 joins the fight against cervix cancer. *Expert Rev Vaccines* 2015;14:1047-9.
[PUBMED](#) | [CROSSREF](#)
10. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med* 2015;372:711-23.
[PUBMED](#) | [CROSSREF](#)
11. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst* 2010;102:325-39.
[PUBMED](#) | [CROSSREF](#)
12. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. *Vaccine* 2012;30 Suppl 5:F12-23.
[PUBMED](#) | [CROSSREF](#)
13. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer* 2017;141:664-70.
[PUBMED](#) | [CROSSREF](#)
14. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:1157-64.
[PUBMED](#) | [CROSSREF](#)
15. Monsonego J, Zerat L, Syrjänen K, Zerat JC, Smith JS, Halfon P. Prevalence of genotype-specific HPV infection among women in France: implications for screening and vaccination. *Gynecol Obstet Fertil* 2013;41:305-13.
[PUBMED](#) | [CROSSREF](#)
16. Kim MJ, Kim JJ, Kim S. Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: data from the health check-ups of 7,014 Korean women. *Obstet Gynecol Sci* 2013;56:110-20.
[PUBMED](#) | [CROSSREF](#)
17. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. *JAMA* 2002;287:2114-9.
[PUBMED](#) | [CROSSREF](#)

18. Kwon MJ, Roh KH, Park H, Woo HY. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection. *J Clin Virol* 2014;59:246-9.
[PUBMED](#) | [CROSSREF](#)
19. Hang D, Jia M, Ma H, Zhou J, Feng X, Lyu Z, et al. Independent prognostic role of human papillomavirus genotype in cervical cancer. *BMC Infect Dis* 2017;17:391.
[PUBMED](#) | [CROSSREF](#)
20. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol* 2010;11:1048-56.
[PUBMED](#) | [CROSSREF](#)
21. Oh JK, Alemany L, Suh JI, Rha SH, Muñoz N, Bosch FX, et al. Type-specific human papillomavirus distribution in invasive cervical cancer in Korea, 1958–2004. *Asian Pac J Cancer Prev* 2010;11:993-1000.
[PUBMED](#)
22. So KA, Hong JH, Lee JK. Human papillomavirus prevalence and type distribution among 968 women in South Korea. *J Cancer Prev* 2016;21:104-9.
[PUBMED](#) | [CROSSREF](#)
23. Krashias G, Koptides D, Christodoulou C. HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. *BMC Infect Dis* 2017;17:346.
[PUBMED](#) | [CROSSREF](#)
24. Kjør SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? *Cancer Causes Control* 2014;25:179-89.
[PUBMED](#) | [CROSSREF](#)
25. Rhee JE, Shin MY, Kim CM, Kee HY, Chung JK, Min SK, et al. Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development. *Virology* 2010;7:201.
[PUBMED](#) | [CROSSREF](#)
26. Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. *J Microbiol Biotechnol* 2008;18:788-94.
[PUBMED](#)
27. Lee HS, Kim KM, Kim SM, Choi YD, Nam JH, Park CS, et al. Human papillomavirus genotyping using HPV DNA chip analysis in Korean women. *Int J Gynecol Cancer* 2007;17:497-501.
[PUBMED](#) | [CROSSREF](#)
28. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. *J Infect Dis* 2004;190:468-76.
[PUBMED](#) | [CROSSREF](#)
29. Zappacosta R, Lattanzio G, Viola P, Ianieri MM, Gatta DM, Rosini S. A very rare case of HPV-53-related cervical cancer, in a 79-year-old woman with a previous history of negative Pap cytology. *Clin Interv Aging* 2014;9:683-8.
[PUBMED](#) | [CROSSREF](#)
30. Song ES, Lee HJ, Hwang TS. Clinical efficacy of human papillomavirus DNA detection in urine from patients with various cervical lesions. *J Korean Med Sci* 2007;22:99-104.
[PUBMED](#) | [CROSSREF](#)
31. Estrade C, Sahli R, McAdam AJ. Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping. *J Clin Microbiol* 2014;52:607-12.
[PUBMED](#) | [CROSSREF](#)
32. Lillsunde Larsson G, Carlsson J, Karlsson MG, Helenius G. Evaluation of HPV genotyping assays for archival clinical samples. *J Mol Diagn* 2015;17:293-301.
[PUBMED](#) | [CROSSREF](#)